As the world watches and waits for a vaccine, we ask what IR is like under the pandemic spotlight
‘The scrutiny is extraordinarily high,’ says Nick Mazing, director of research at Sentieo, talking about the media and market focus on pharmaceuticals and biotech firms involved in the fight against Covid-19. ‘And it’s not just scrutiny. It is interference.’
As the world waits with hope for big pharma and its smaller, more dynamic biotech cousins to free us from the confines of the coronavirus, the companies involved in producing vaccines or therapeutics have seen demanding new stakeholders
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495
Garnet Roach
An award-winning journalist, Garnet Roach joined IR Magazine in October 2012, working on both the editorial and research sides of the publication. Prior to entering the world of investor relations, her freelance career covered a broad range of...
Deputy editor
